Grail taps Genen­tech vet Jen­nifer Cook as CEO, build­ing ex­pec­ta­tions for 2018

Af­ter a cu­ri­ous se­ries of C-suite de­par­tures, Sil­i­con Val­ley’s Grail has locked in on some­one whom it trusts to lead the can­cer de­tec­tion biotech in­to com­mer­cial op­er­a­tions: Jen­nifer Cook. Cook re­places in­ter­im CEO Bill Rastet­ter, the Il­lu­mi­na ad­vi­sor who stepped in af­ter found­ing CEO Jeff Hu­ber re­signed in Au­gust.

If her re­sume is any in­di­ca­tion, Cook is here to stay. An ear­ly devo­tee to biotech, she has worked at Genen­tech pret­ty much her whole ca­reer (mi­nus a four-year stint at a start­up ear­ly on), join­ing in 1987 and mov­ing to Roche in 2013, af­ter Genen­tech had be­come a sub­sidiary.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Associate

Alexandria Real Estate Equities

San Diego, CA, USA